Figure S3 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Year: 2023
Type: other
Abstract: Representative venetoclax-resistant (BJAB and HT) cell lines were treated with venetoclax at a 1:1 ratio drug combinations with PI3K inhibitors (idelalisib and KA2237) or an AKT inhibitor (MK-2206) in a concentration-dependent manner for 72 h, and cell viability was assessed. The highest starting concentration for each drug was 20 mM. The following are the drug combinations: 100 nM: 20 mM; 50 nM:10 mM; 25 nM:5 mM; 12.5 nM:2.5 mM; 6.25 nM:1.25 mM; 3.1 nM:0.61 mM; 1.5 nM:0.3 mM. Data from two independent experiments performed in triplicate are shown. (B) MAPK-pT202-Y204, MEK1-pS217-S221, and JNK-pT183-Y185 protein levels were plotted against the corresponding venetoclax IC50 for each cell line. Spearman's rank correlation coefficient, and p values determined of the above analysis. P values less than 0.05 indicate significant correlations.
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362432831